In a comparison between primary sweat gland tumors and metastatic breast carcinoma to skin, Busam et al.[13,19] found that the use of antibodies against epidermal growth factor receptor strongly decorated 81% of sweat gland tumors, but only 17% of metastatic breast cancers (P=0.001). The gene discussed is EGFR; the disease is sweat gland neoplasm.